AnaptysBio (NASDAQ:ANAB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of AnaptysBio (NASDAQ:ANAB) from a hold rating to a buy rating in a report released on Saturday morning,Wall Street Zen reports.

Several other research analysts have also weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. Leerink Partners decreased their price objective on AnaptysBio from $90.00 to $81.00 and set an “outperform” rating for the company in a research report on Wednesday, September 23rd. Scotiabank cut AnaptysBio to a “hold” rating and set a $70.00 target price on the stock. in a research note on Tuesday, August 25th. HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of AnaptysBio in a research note on Tuesday, September 22nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of AnaptysBio in a report on Friday, August 7th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.15.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $50.80 on Friday. The firm’s 50 day moving average price is $55.39 and its two-hundred day moving average price is $59.00. AnaptysBio has a twelve month low of $15.43 and a twelve month high of $72.36. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of 9.46 and a beta of 0.71.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $5.57. The company had revenue of $27.49 million during the quarter, compared to analyst estimates of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%.During the same quarter in the prior year, the company earned ($1.30) earnings per share. On average, research analysts forecast that AnaptysBio will post -1.48 EPS for the current fiscal year.

Institutional Trading of AnaptysBio

Several hedge funds and other institutional investors have recently modified their holdings of the company. First Light Asset Management LLC raised its stake in shares of AnaptysBio by 2.9% during the 2nd quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock worth $39,285,000 after purchasing an additional 16,573 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in shares of AnaptysBio by 21.2% during the 2nd quarter. Squarepoint Ops LLC now owns 324,446 shares of the biotechnology company’s stock valued at $21,900,000 after buying an additional 56,743 shares during the last quarter. Arizona State Retirement System grew its stake in shares of AnaptysBio by 13.5% in the 2nd quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock valued at $295,000 after buying an additional 518 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of AnaptysBio in the 2nd quarter valued at approximately $1,164,000. Finally, Irenic Capital Management LP acquired a new position in AnaptysBio in the second quarter worth approximately $4,755,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.